NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway
Cancer Science · 2024
DOI: 10.1111/cas.16040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Xianchao Sun und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Prostatic Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Docetaxel is the preferred chemotherapeutic agent in patients with castrate‐resistant prostate cancer (CRPC). However, patients eventually develop docetaxel resistance and in the absence of effective treatment options. Consequently, it is essential to investigate the mechanisms generating docetaxel resistance and develop novel alternative therapeutic targets. RNA sequencing was undertaken on docetaxel‐sensitive and docetaxel‐resistant prostate cancer (PCa) cells. Subsequently, chemoresistance, cancer stemness, and lipid metabolism were investigated. To obtain insight into the precise activities and action mechanisms of NOTCH3 in docetaxel‐resistant PCa, immunoprecipitation, mass spectrometry, ChIP, luciferase reporter assay, cell metabolism, and animal experiments were performed. Through RNA sequencing analysis, we found that NOTCH3 expression was markedly higher in docetaxel‐resistant cells relative to parental cells, and that this trend was continued in docetaxel‐resistant PCa tissues. Experiments in vitro and in vivo revealed that NOTCH3 enhanced stemness, lipid metabolism, and docetaxel resistance in PCa. Mechanistically, NOTCH3 is bound to TUBB3 and activates the MAPK signaling pathway. Moreover, NOTCH3 was directly regulated by MEF2A in docetaxel‐resistant cells. Notably, targeting NOTCH3 and the MEF2A/TUBB3 signaling axis was related to docetaxel chemoresistance in PCa. Overall, these results demonstrated that NOTCH3 fostered stemness, lipid metabolism, and docetaxel resistance in PCa via the TUBB3 and MAPK signaling pathways. Therefore, NOTCH3 may be employed as a prognostic biomarker in PCa patients. NOTCH3 could be a therapeutic target for PCa patients, particularly those who have developed docetaxel resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
- Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Pathology, The Third Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
- Department of Urology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
ORCID-Profile: Lin Ye
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, X., Zhang, Y., Xin, S., Jin, L., Cao, Q., Wang, H., Wang, K., Liu, X., Tang, C., Li, W., Li, Z., Wen, X., Yang, G., Guo, C., Liu, Z., & Ye, L. (2024). NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway. Cancer Science. https://doi.org/10.1111/cas.16040
Vancouver
Sun X, Zhang Y, Xin S, Jin L, Cao Q, Wang H, et al. NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway. Cancer Science. 2024. doi:10.1111/cas.16040
BibTeX
@article{Sun2024,
author = {Sun, Xianchao and Zhang, Ying and Xin, Shiyong and Jin, Liang and Cao, Qiong and Wang, Hong and Wang, Keyi and Liu, Xiang and Tang, Chaozhi and Li, Weiyi and Li, Ziyao and Wen, Xiaofei and Yang, Guosheng and Guo, Changcheng and Liu, Zhiyu and Ye, Lin},
title = {NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16040}
}
EUVIMED